The Technical Analyst
Olink Holding AB (publ) [OLK]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Olink Holding AB (publ) Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.91% $21.85
America/New_York / 19 apr 2024 @ 15:56
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 716.27 mill |
| EPS: | -0.250 |
| P/E: | -87.38 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 124.34 mill |
| Avg Daily Volume: | 0.645 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -87.38 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -4.67x |
| Company: PE -87.38 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 21.42 - 22.22 ( +/- 1.82%) |
| ATR Model: 14 days |
Forecast:
16:00 - $21.84
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $21.84
Forecast 2: 16:00 - $21.84
Forecast 3: 16:00 - $21.84
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $21.85 (-1.91% ) |
| Volume | 0.570 mill |
| Avg. Vol. | 0.645 mill |
| % of Avg. Vol | 88.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OLK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $24.42 | N/A | Active |
|---|
OLK
Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data. Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.
Latest Press Releases
2024-03-25 08:00:00 - Press Release
Olink Reports Fourth Quarter And Full Year 2023 Financial Results
Uppsala, sweden, march 25, 2024 (globe newswire) -- olink holding ab (publ) (“olink”) (nasdaq: olk) today announced its unaudited financial results for the fourth quarter ended december 31, 2023.
2024-03-15 08:00:00 - Press Release
Notice To Attend The Annual General Meeting Of Olink Holding Ab (publ)
Uppsala, sweden, march 15, 2024 (globe newswire) -- the shareholders of olink holding ab (publ) (the “company” or “olink”), reg. no. 559189-7755, are hereby given notice to attend the annual general meeting to be held at 4:00 p.m. cet on friday the 19 april 2024, in the company's facilities at salagatan 16a, uppsala. registration for the meeting commences at 3:30 p.m. cet.
2024-03-08 08:00:00 - Press Release
Olink Announces Change Of Date For Annual General Meeting
Uppsala, sweden, march 08, 2024 (globe newswire) -- olink holding ab (publ) (“olink”) (nasdaq: olk), today announced that olink's 2024 annual general meeting (“agm”) will be held in uppsala, sweden on april 19th, 2024. the agm was previously scheduled to take place on april 17th, 2024.
2023-11-15 07:00:00 - Press Release
Olink Reports Third Quarter 2023 Financial Results
Uppsala, sweden, nov. 15, 2023 (globe newswire) -- olink holding ab (publ) (“olink”) (nasdaq: olk) today announced its unaudited financial results for the third quarter ended september 30, 2023.
2023-11-05 20:00:00 - Press Release
Novogene Asia Pacific Middle East And Africa Adopts Olink® Explore Ht Technology To Accelerate Multi-omics Research With Next Generation Proteomics
Novogene amea to begin offering olink explore ht high-throughput proteomics services to unravel the connections between genes, proteins, and diseases.
Latest News
2023-12-30 09:30:00 - The Motley Fool
Forget Quantum-Si Stock, Olink Acquirer Thermo Fisher Is a Better Long-Term Investment
Quantum-Si has a ton of promise if the proteomics market continues to develop. Thermo Fisher indicated the future potential with its big pending acquisition of Olink.
2023-11-03 05:20:00 - The Motley Fool
Should You Still Buy the Nasdaq's Best-Performing October Stocks?
Structure Therapeutics' weight-loss drug candidate is attracting attention over excitement about obesity treatments. ImmunityBio rallied on hopes that its bladder cancer drug will now be better understood by the FDA.
2023-10-17 11:29:41 - The Motley Fool
Why Olink Stock Is Skyrocketing Today
Thermo Fisher Scientific plans to acquire Olink for $3.1 billion. The deal would add Olink's proteomics technology to Thermo Fisher's life sciences solutions.
2023-08-12 10:03:18 - Seeking Alpha
Olink Holding AB (publ) (OLK) Q2 2023 Earnings Call Transcript
Olink Holding AB (publ) (NASDAQ:OLK ) Q2 2023 Earnings Conference Call August 9, 2023 8:00 AM ET Company Participants Jan Medina - VP, IR & Capital Markets Jon Heimer - CEO & Director Carl Raimond - President Oskar Hjelm - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Puneet Souda - Leerink Partners Sung Ji Nam - Scotiabank Matthew Sykes - Goldman Sachs Group Yuko Oku - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Olink Proteomics Q2 2023 Earnings Conference Call.
2023-07-25 11:39:34 - Zacks Investment Research
Wall Street Analysts Believe Olink Holding AB (publ) Sponsored ADR (OLK) Could Rally 31.22%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 31.2% in Olink Holding AB (publ) Sponsored ADR (OLK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-07-13 08:00:00 - GlobeNewsWire
Olink to report second quarter 2023 financial results on August 9, 2023, and to participate in the Canaccord Genuity 43rd Annual Growth Conference
UPPSALA, Sweden, July 13, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the second quarter of 2023 before the market open on Wednesday, August 9, 2023. Company management will host a conference call to discuss these results at 8:00 am ET.
2023-05-14 04:13:39 - Seeking Alpha
Olink Holding AB (publ) (OLK) Q1 2023 Earnings Call Transcript
Olink Holding AB (publ) (NASDAQ:OLK ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Jan Medina - Vice President of Investor Relations and Capital Markets Jon Heimer - Chief Executive Officer Carl Raimond - President Oskar Hjelm - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Leerink Sung Ji Nam - Scotiabank Kyle Mikson - Canaccord Genuity Ivy Kozlowski - Goldman Sachs Operator Good morning, and thank you for standing by. Welcome to the Olink Proteomics Fourth Quarter 2022 Earnings Conference Call.
2023-05-11 09:56:22 - Zacks Investment Research
Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q1 Loss, Tops Revenue Estimates
Olink Holding AB (publ) Sponsored ADR (OLK) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.10 per share a year ago.
2023-04-24 13:41:31 - Zacks Investment Research
Olink Holding AB (publ) Sponsored ADR (OLK) Moves to Strong Buy: Rationale Behind the Upgrade
Olink Holding AB (publ) Sponsored ADR (OLK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-04-13 08:00:00 - GlobeNewsWire
Olink to report first quarter 2023 financial results on May 11, 2023
UPPSALA, Sweden, April 13, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the first quarter of 2023 before the market open on Thursday, May 11, 2023. Company management will host a conference call to discuss these results at 8:00 am ET.